Compare ALEMBIC with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs LUPIN - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LUPIN ALEMBIC/
LUPIN
 
P/E (TTM) x 60.4 -301.4 - View Chart
P/BV x 5.2 3.9 132.6% View Chart
Dividend Yield % 0.2 0.6 35.5%  

Financials

 ALEMBIC   LUPIN
EQUITY SHARE DATA
    ALEMBIC
Mar-18
LUPIN
Mar-20
ALEMBIC/
LUPIN
5-Yr Chart
Click to enlarge
High Rs72882 8.2%   
Low Rs34505 6.7%   
Sales per share (Unadj.) Rs4.7339.4 1.4%  
Earnings per share (Unadj.) Rs6.1-5.9 -102.6%  
Cash flow per share (Unadj.) Rs6.215.5 40.4%  
Dividends per share (Unadj.) Rs0.206.00 3.3%  
Dividend yield (eoy) %0.40.9 43.7%  
Book value per share (Unadj.) Rs40.7276.7 14.7%  
Shares outstanding (eoy) m267.03453.00 58.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x11.32.0 551.2%   
Avg P/E ratio x8.7-116.6 -7.4%  
P/CF ratio (eoy) x8.544.8 18.9%  
Price / Book Value ratio x1.32.5 52.0%  
Dividend payout %3.3-100.9 -3.2%   
Avg Mkt Cap Rs m14,139314,201 4.5%   
No. of employees `000NA18.3 0.0%   
Total wages/salary Rs m20729,868 0.7%   
Avg. sales/employee Rs ThNM8,400.6-  
Avg. wages/employee Rs ThNM1,632.0-  
Avg. net profit/employee Rs ThNM-147.2-  
INCOME DATA
Net Sales Rs m1,255153,748 0.8%  
Other income Rs m3704,838 7.7%   
Total revenues Rs m1,625158,585 1.0%   
Gross profit Rs m11124,849 0.4%  
Depreciation Rs m389,702 0.4%   
Interest Rs m23,630 0.0%   
Profit before tax Rs m44216,355 2.7%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m1,21239 3,076.1%   
Extraordinary Inc (Exp) Rs m0-7,521 0.0%   
Tax Rs m2411,571 0.2%   
Profit after tax Rs m1,630-2,694 -60.5%  
Gross profit margin %8.916.2 54.8%  
Effective tax rate %5.470.8 7.7%   
Net profit margin %129.8-1.8 -7,410.7%  
BALANCE SHEET DATA
Current assets Rs m1,867154,132 1.2%   
Current liabilities Rs m59192,252 0.6%   
Net working cap to sales %101.640.2 252.6%  
Current ratio x3.21.7 189.0%  
Inventory Days Days9482 114.8%  
Debtors Days Days74129 56.9%  
Net fixed assets Rs m1,79189,082 2.0%   
Share capital Rs m534906 59.0%   
"Free" reserves Rs m10,324124,461 8.3%   
Net worth Rs m10,858125,367 8.7%   
Long term debt Rs m4117,933 0.2%   
Total assets Rs m11,591249,839 4.6%  
Interest coverage x260.95.5 4,738.4%   
Debt to equity ratio x00.1 2.7%  
Sales to assets ratio x0.10.6 17.6%   
Return on assets %14.10.4 3,757.8%  
Return on equity %15.0-2.1 -698.6%  
Return on capital %15.28.7 174.0%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1951,450 0.0%   
Fx outflow Rs m26419,470 1.4%   
Net fx Rs m-24431,980 -0.8%   
CASH FLOW
From Operations Rs m23614,688 1.6%  
From Investments Rs m-22411,070 -2.0%  
From Financial Activity Rs m-27-8,906 0.3%  
Net Cashflow Rs m-1516,853 -0.1%  

Share Holding

Indian Promoters % 64.0 46.6 137.3%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 0.2 11.3 1.8%  
FIIs % 9.7 31.9 30.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 10.1 258.4%  
Shareholders   54,701 98,259 55.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   DIVIS LABORATORIES  WOCKHARDT  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare ALEMBIC With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends at Record High; Tata Motors and Adani Ports Among Top Nifty Gainers(Closing)

Indian share markets extended gains to the second day today and ended at record-high levels with Nifty ending above 14,600-mark.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Jan 20, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC - BIOCON COMPARISON

COMPARE ALEMBIC WITH

MARKET STATS